Sartorius Stedim Biotech SA/ FR0013154002 /
| 2024-12-27 4:04:55 PM | Chg. +3.55 | Volume | Bid4:05:22 PM | Ask4:05:21 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 187.85EUR | +1.93% | 17,968 Turnover: 3.36 mill. |
187.80Bid Size: 40 | 187.90Ask Size: 1 | 17.33 bill.EUR | 0.37% | 55.97 |
Assets
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 546.6000 | 644.4000 | 928.4000 | 1,292 | 1,633.2000 | ||||||
| Intangible Assets | 180.1000 | 633.5000 | 684.4000 | 876.8000 | 1,736.2000 | ||||||
| Long-Term Investments | 15.1000 | 13.5000 | 14.8000 | 24.9000 | 40.8000 | ||||||
| Fixed Assets | - | - | 2,495.5000 | 3,394.2000 | 6,324.8000 | ||||||
| Inventories | 328.2000 | 472.3000 | 783 | 1,024.8000 | 882.4000 | ||||||
| Accounts Receivable | 220.8000 | 256.9000 | 356 | 404.6000 | 293.7000 | ||||||
| Cash and Cash Equivalents | 27.6000 | 59.8000 | 223.6000 | 107.1000 | 116.6000 | ||||||
| Current Assets | 633.8000 | 875.2000 | 1,455.6000 | 1,671.2000 | 1,415.1000 | ||||||
| Total Assets | 1,820.4000 | 3,069.3000 | 3,951.1000 | 5,065.4000 | 7,739.9000 | ||||||
Liabilities
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 196.6000 | 307 | 471.2000 | 485.6000 | 444.5000 | ||||||
| Long-term debt | 130.6000 | 819 | 1,003.6000 | 1,292.9000 | 3,509.7000 | ||||||
| Liabilities to Banks | 214.8000 | 861.3000 | - | - | - | ||||||
| Provisions | 100.5000 | 197.3000 | 208.1000 | 248 | 458 | ||||||
| Liabilities | 642.8000 | 1,586.4000 | 2,217.9000 | 2,551.2000 | 5,066.7000 | ||||||
| Share Capital | 18.4360 | 18.4360 | 18.4360 | - | - | ||||||
| Total Equity | 1,177.6000 | 1,482.9000 | 1,655.9000 | 2,449.3000 | 2,637.9000 | ||||||
| Minority Interests | 18.8000 | 22.9000 | 77.4000 | 64.9000 | 35.3000 | ||||||
| Total liabilities equity | 1,820.4000 | 3,069.3000 | 3,951.1000 | 5,065.4000 | 7,739.9000 | ||||||
Income Statement
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,440.6000 | 1,910.1000 | 2,887 | 3,492.7000 | 2,775.5000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 332 | 471.8000 | 865.4000 | 995.2000 | 448.7000 | ||||||
| Interest Income | - | - | -218.7000 | 135.1000 | -47.5000 | ||||||
| Income Before Taxes | 317.6000 | 482.6000 | - | - | - | ||||||
| Income Taxes | 81.4000 | 122.1000 | 232.4000 | 250.5000 | 89 | ||||||
| Minority Interests Profit | -1.6000 | -2.7000 | -1.4000 | -3.8000 | 2.4000 | ||||||
| Net Income | 234.6000 | 357.8000 | 414.3000 | 876.1000 | 309.7000 | ||||||
Per Share
Cash Flow
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 310.1000 | 416.9000 | 696 | 612.3000 | 746.4000 | ||||||
| Cash Flow from Investing Activities | -136 | -150.5000 | -323.6000 | -442 | -481.8000 | ||||||
| Cash Flow from Financing | -122.2000 | 234.1000 | -71.7000 | 220.7000 | 1,986.1000 | ||||||
| Decrease / Increase in Cash | 3.1000 | 29.8000 | - | - | - | ||||||
| Employees | 6,203 | 6,900 | 10,409 | 11,934 | 10,662 | ||||||
